about
Drug development against the hippo pathway in mesotheliomaCDK9: A key player in Cancer and Other Diseases.Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors.CDK9-dependent RNA polymerase II pausing controls transcription initiation.In vitro and in vivo anti-tumor and anti-inflammatory capabilities of the novel GSK3 and CKD9 inhibitor ABC1183.CDK9 inhibitors in acute myeloid leukemia.MicroRNA-613 inhibits the progression of gastric cancer by targeting CDK9.The anti-human cytomegalovirus drug tricin inhibits cyclin-dependent kinase 9.MicroRNA-874 inhibits cell proliferation and invasion by targeting cyclin-dependent kinase 9 in osteosarcoma.The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells.Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia.CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant ChemotherapyA Systems Approach to Study Immuno- and Neuro-Modulatory Properties of Antiviral Agents
P2860
Q39438182-772886CC-D0DA-466D-BE0D-F2A305C5AB38Q40117228-1C5AD13A-0CED-4EE5-85AB-D33B7937DAE1Q42367759-0C02C077-4CFE-492C-8EAB-7E4F440BE436Q46420204-58DED5DB-4C17-4E89-BE92-3EEC1CF23E52Q47098738-6628334F-0D20-4EDA-A2A0-12FE14EB7705Q47111692-08555D32-48F7-425F-9B11-008DB26B0C37Q50056226-18061E6D-0E13-4434-B468-B922ECB1A87EQ50318294-1F90FE58-181F-4774-87C4-ECC20F02A579Q53166772-4D90630D-47F6-4E01-AFB3-66ABC9B04089Q53831437-8B718D16-7819-436D-BD5F-CF342E22AD1CQ54112430-5D9F5FD6-9F9E-4582-9736-BA17D6D65397Q54977960-57633AB6-D466-40F1-9606-B2CA5357E6FEQ55280895-85BF1AAB-1BC2-432A-86C9-86463DA671C4Q58567485-05E01ECB-51ED-466A-997A-B6DA761469DAQ58787671-8B5385B8-1F73-4E2A-A8B7-1524CC261187
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Overview of CDK9 as a target in cancer research.
@en
type
label
Overview of CDK9 as a target in cancer research.
@en
prefLabel
Overview of CDK9 as a target in cancer research.
@en
P2860
P1433
P1476
Overview of CDK9 as a target in cancer research
@en
P2093
Fatima Morales
P2860
P304
P356
10.1080/15384101.2016.1138186
P577
2016-01-01T00:00:00Z